{"transactions":[{"id":1811760,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":110698,"kind":"person","name":"Marshall Ken W.","position":1,"cik":"0001740092","reported_name":"Marshall Ken W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Performance Stock Units","published_at":"2023-08-09T20:30:32.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance-based stock unit (\"PSU\") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance-based stock unit (\"PSU\") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period."}],"balance_after":75000,"derivative":{"expiration_date":"2026-05-05","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001214659-23-010921","document":"marketforms-61882.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000121465923010921/marketforms-61882.xml","form_type":"4"}},{"id":1902271,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":110698,"kind":"person","name":"Marshall Ken W.","position":1,"cik":"0001740092","reported_name":"Marshall Ken W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Performance Stock Units","published_at":"2023-05-05T20:00:22.000Z","date":"2023-05-05","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of Aquestive (\"Company\") common stock. The PSUs have a three-year Performance Period, and, to the extent\nearned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the\nlast day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results\nof the Performance Price. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior\nto and including the last calendar day of the Performance Period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of Aquestive (\"Company\") common stock. The PSUs have a three-year Performance Period, and, to the extent\nearned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the\nlast day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results\nof the Performance Price. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior\nto and including the last calendar day of the Performance Period."}],"balance_after":75000,"derivative":{"expiration_date":"2026-05-05","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001214659-23-006553","document":"marketforms-61239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000121465923006553/marketforms-61239.xml","form_type":"4"}},{"id":1960668,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":110698,"kind":"person","name":"Marshall Ken W.","position":1,"cik":"0001740092","reported_name":"Marshall Ken W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-09T20:07:46.000Z","date":"2023-03-09","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment."}],"balance_after":150000,"source":{"system":"sec-edgar","filing":"0001214659-23-003694","document":"marketforms-59527.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000121465923003694/marketforms-59527.xml","form_type":"4"}},{"id":2122041,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":110698,"kind":"person","name":"Marshall Ken W.","position":1,"cik":"0001740092","reported_name":"Marshall Ken W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-11-08T15:23:09.000Z","date":"2022-11-04","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment."}],"balance_after":40000,"derivative":{"exercise_price":0.875,"expiration_date":"2032-11-04","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001214659-22-013280","document":"marketforms-57372.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000121465922013280/marketforms-57372.xml","form_type":"4"}},{"id":2335003,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":110698,"kind":"person","name":"Marshall Ken W.","position":1,"cik":"0001740092","reported_name":"Marshall Ken W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-03-14T15:25:36.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment."}],"balance_after":80000,"derivative":{"exercise_price":2.55,"expiration_date":"2032-03-10","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001214659-22-003897","document":"marketforms-55763.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000121465922003897/marketforms-55763.xml","form_type":"4"}},{"id":2788828,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":110698,"kind":"person","name":"Marshall Ken W.","position":1,"cik":"0001740092","reported_name":"Marshall Ken W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-03-15T21:10:37.000Z","date":"2021-03-11","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment."}],"balance_after":40000,"derivative":{"exercise_price":5.3,"expiration_date":"2031-03-11","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001214659-21-003152","document":"marketforms-51880.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000121465921003152/marketforms-51880.xml","form_type":"4"}},{"id":3201956,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":110698,"kind":"person","name":"Marshall Ken W.","position":1,"cik":"0001740092","reported_name":"Marshall Ken W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2020-03-18T20:46:56.000Z","date":"2020-03-16","kind":"grant","acquired":true,"shares":45400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries."}],"balance_after":45400,"derivative":{"exercise_price":1.54,"expiration_date":"2030-03-16","underlying":"Common Stock","underlying_shares":45400},"source":{"system":"sec-edgar","filing":"0001214659-20-002750","document":"marketforms-48346.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000121465920002750/marketforms-48346.xml","form_type":"4"}},{"id":3408824,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":110698,"kind":"person","name":"Marshall Ken W.","position":1,"cik":"0001740092","reported_name":"Marshall Ken W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-09-20T20:30:15.000Z","date":"2019-09-18","kind":"grant","acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment."}],"balance_after":66000,"derivative":{"exercise_price":3.49,"expiration_date":"2029-09-18","underlying":"Common Stock","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001214659-19-005969","document":"marketforms-45791.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000121465919005969/marketforms-45791.xml","form_type":"4"}},{"id":3745582,"issuer":{"id":5276,"kind":"organization","name":"Aquestive Therapeutics, Inc.","symbol":"AQST"},"owners":[{"id":110698,"kind":"person","name":"Marshall Ken W.","position":1,"cik":"0001740092","reported_name":"Marshall Ken W.","relationship":{"officer":true,"officer_title":"Commercial Leader"}}],"security":"Common Stock","published_at":"2018-12-03T21:01:29.000Z","date":"2018-11-21","kind":"purchase","acquired":true,"shares":1445,"price":10.15,"value":14666.75,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by the Tasro Consulting, LLC 401(k) Plan, Kenneth Marshall Trustee, f/b/o Kenneth Marshall."}],"balance_after":1445,"source":{"system":"sec-edgar","filing":"0001140361-18-044399","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398733/000114036118044399/form4.xml","form_type":"4"}}]}